Abstract: The invention provides a process for preparing silicon particles comprising at least one drug substance, wherein said process comprises the steps: a) preparing silicon particles via chemical vapor deposition (CVD): b) loading the silicon particles prepared in step a) with at least one drug substance.

Abstract: Cyclosporine containing nanoparticles and methods for making and using the same are provided.

Abstract: Provided herein are oral compositions comprising zolmitriptan, and methods of use thereof e.g., for the treatment of the symptoms of autism spectrum disorder, and the treatment of aggression in patients with dementia.

Abstract: This disclosure relates to nanoparticles for preventing, treating and reversing atherosclerosis.

Abstract: Provided herein are methods of reducing adduct formation in lipid nanoparticle compositions comprising a polynucleotide, such as mRNA, and an ionizable lipid; also disclosed are lipid nanoparticle compositions having a reduced adduct content, and methods of detecting the adducts.

Abstract: The present invention relates to a composition comprising an oligo(ethylene glycol)-based polymers microgel crosslinked with a catechol cross-linker, said microgel comprises microgel particles, and wherein the microgel particles have a shell of conductive polymer. This composition is able to form cohesive films spontaneously with enhanced conductive and mechano-electrical properties.

Abstract: A lipid compound or a derivative thereof and a pharmaceutical composition employing the same are provided. The lipid compound has a structure represented by Formula (I): wherein Z1, Z2, Z3 and Z4 are as disclosed in the specification.

Abstract: The present invention relates to a water resistant wound cover with high comfort and good air permeability. In particular, the present invention relates to an aqueous wound healing formulation comprising a water-soluble or a water-dispersible polymeric material that does not sting when applied to a minor injury to the skin.

Abstract: Described herein are virus-like particles (VLPs) and minimal human-derived virus-like particles (mhVLPs), comprising a membrane comprising a phospholipid bilayer with one or more human-derived envelope glycoproteins (env) on the external side. Optionally, a biomolecule cargo is disposed in the core of the VLP or mhVLP on the inside of the membrane. Preferably, the mhVLPs do not comprise any exogenous virally derived proteins, e.g., proteins from viral gag, pro, or pol, or other viral proteins that reside inside of enveloped particles (unless the cargo comprises the viral protein(s)). In some embodiments, the mhVLPs do not comprise any human endogenous retroviral (HERV) proteins other than the env (hENV), e.g., do not comprise gag, pol, or pro that was exogenously introduced into producer cells. In some embodiments, the VLPs include a targeting domain, either fused at the N or C terminus or internally into the hENV, or as a separate membrane-anchored targeting domain.

Abstract: Compositions, devices, and methods for transdermal administration of olanzapine and uses thereof, e.g., to treat nausea and vomiting.

Abstract: The disclosure describes a method of removing and/or replacing an organic ligand from a surface of metal oxide nanoparticles. The method involves mixing a sample of metal oxide nanoparticles comprising an organic ligand in a liquid comprising an organic phase and an aqueous phase, the aqueous phase comprising at least one stripping agent, wherein mixing occurs under conditions to cause the stripping agent to interact with the surface of the metal oxide nanoparticles; removing the aqueous phase from the organic phase following mixing; and optionally, drying the aqueous phase removed from the organic phase.

Abstract: Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.

Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.

Abstract: In an illustrative embodiment, systems and methods for treatment of nerves present in a wall of a human renal pelvis are described. One system uses a sheath to access a position in or near the renal pelvis via the urinary tract. An effector inserted through the sheath has an uncooled distal region formed with a superelastic wire that supports at least four non-insulated, preferably spherical electrodes distributed along the distal region. The distal region expands within the renal pelvis, and vacuum applied through the sheath at least partially evacuates the renal pelvis to draw opposing walls of the renal pelvis inwards and compress the distal region somewhat from its expanded form, placing the electrodes in intimate contact with different points along the renal pelvic wall. Energy is applied to the electrodes to create discrete lesions at the points of contact of the electrodes.

Abstract: Compositions and methods disclosed herein are configured to be administered to a subject prior to surgery. Compositions and methods disclosed herein are configured to provide nutrition and counteract physiological effects of a surgery. Compositions and methods disclosed herein can enable a subject to mitigate the stress response responsible for drastic shifts in metabolic and biochemical pathways, which can often leave a subject susceptible to a risk of higher mortality.

Abstract: A solution for ocular application containing xylitol. Topically applied to the eye, the solution improves the quality of the ocular tear film, and reduces the incidence of infectious organisms, including bacterial abnormal colonization, acanthamoeba and an assortment of infective virus types including SARS, SARS-Cov-2. The same solution may also be applied to eyes of contact lens wearers and within the contact lens storage solutions to reduce the incidence of infection and in eyes with sicca syndromes demonstrating tear film poor lipid quantity or quality with meibomian gland dysfunction and in eyes demonstrating evidence of inflammation of the margins or posterior lid mucosal surfaces indicating blepharitis. The solution may be also applied to the lid margins with heat and ocular scrubbing massage in the case of eyes demonstrating blepharitis.

Abstract: The invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of nephropathy in mammals. The composition further comprises ?-glucogallin and total mucic acid gallates, C-glucosides and tannins isolated from Pterocarpus marsupium. The invention also discloses the potential of the composition comprising ?-glucogallin and total mucic acid gallates from Emblica officinalis, C-glucosides and tannins isolated from Pterocarpus marsupium in the therapeutic management of nephropathy.

Abstract: Phytol contained in watermelon sprouts is known to have an antiproliferative effect on cancer cell. However, there has been a problem in that a high dose is required to exert the antiproliferative effect on cancer cell. A cancer cell growth-inhibiting composition including a substance having structures represented by formulas (1) to (6) has a higher antiproliferative effect on cancer cell than phytol by order of one or more magnitudes. Further, it is expected that these substances do not affect normal cells similarly to phytol. Thus, they are expected to provide an anticancer drug with less side effects.

Abstract: The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

Abstract: Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of a norepinephrine reuptake inhibitor (NRI) and a muscarinic receptor antagonist.